Amicus Therapeutics (FOLD) Proxy Filing summary

Executive summary

• Preliminary unaudited financials estimate $294 million in cash, cash equivalents, and marketable securities as of December 31, 2025.

• Estimated total net product revenues for 2025 are approximately $634 million, with $522 million from Galafold® and $112 million from Pombiliti® + Opfolda®.

• Financial estimates are subject to change pending final accounting and audit procedures.

• The report includes forward-looking statements regarding the proposed acquisition by BioMarin Pharmaceutical Inc.

Voting matters and shareholder proposals

• A preliminary proxy statement was filed for a special meeting to approve the proposed acquisition by BioMarin Pharmaceutical Inc.

• Shareholders are urged to read the definitive proxy statement and related documents for important information about the transaction.

Board of directors and corporate governance

• Information on directors and executive officers, including their interests in the merger, is available in the proxy statement and annual filings.

• Directors and executive officers may be deemed participants in the solicitation of proxies for the transaction.